Edesa Biotech is trading at $2.44, down 5.06%, amid biotech-sector pressure; no company-specific announcement dated November 2 explaining the decline was found.
- Biotech ETF XBI was down 2.39%, consistent with sector pressure.
- The latest company news located was an October 15 FDA clearance for its vitiligo study.
- Edesa Biotech’s October 28 EB05 trial termination was reported as negative near-term context, but available evidence does not establish it as the direct cause of this session’s move.